Texas Royalty Plan: 28 Straight Years of Payment Increases

Clear, systematic insights and strategic market analysis to inform confident investing decisions.

Texas Royalty Plan: 28 Straight Years of Payment Increases – Ad

The Texas Royalty Plan makes payments directly from the oil and gas industry… Available to all Americans. Not just Texas residents. Find out more about the Texas Royalty Plan.

Cathie Wood’s China Bet: Ark Buys Alibaba’s AI Surge And Baidu’s Autonomous Future, Dump’s Stock Of Crypto-Pivot Brera

On Tuesday, Cathie Wood-led Ark Invest made significant trades involving Baidu Inc. (NASDAQ:BIDU), Alibaba Group Holding Ltd. Continue Reading ➔

The Tesla Shock Nobody Sees Coming – Ad

While headlines scream “Tesla is doomed”…Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla’s labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd. See the Tesla shock that could blindside everyone.

Cathie Wood, Tom Lee Align On These 10 Stock Picks: Some Might Surprise You

A new ETF from Tom Lee shares 10 stocks in common with Cathie Wood’s Ark Funds. A look at the stocks both well-known financial figures like. Continue Reading ➔

Trump’s H-1B Visa Plan Stuns Big Tech, White House Says $100,000 Fee Is One-Time Only

The White House clarified that the $100,000 H-1B visa fee is a one-time charge, not an annual fee, amid confusion among major tech companies. Continue Reading ➔

The Man Running the U.S. Dollar… Is Hoarding Gold – Ad

When the U.S. Treasury Secretary’s largest personal holding is gold… that’s known as “a clue.” Warren Buffett sees this. I believe he’s preparing to buy the one gold miner large enough to protect his cash. And here’s the kicker… Confirmation of my prediction could come by November 15. Get the name and ticker of Buffett’s next move into gold.

Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report

Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug portfolio. Continue Reading ➔

Costco, Oracle, IBM, CarMax And BlackBerry: Why These 5 Stocks Are On Investors’ Radars Today

On Thursday, the stock market experienced a downturn, with the S&P 500 and the Nasdaq both closing lower. The Dow Jones also saw a decline of over 170 points. Continue Reading ➔

What’s Going On With Oklo Stock Thursday?

Oklo Inc (NYSE:OKLO) shares are trading lower on Thursday, pulling back from an initial surge following a positive initiation from Canaccord Genuity. Continue Reading ➔

Trump And Musk Reunite, Nuclear Stocks Soar, Kimmel’s Comeback Breaks Records And More: This Week In Politics

It’s been an eventful week with significant developments in the world of politics and late-night television. Continue Reading ➔

One of World’s Richest Men Unlocks “Holy Grail of Power” – Ad

One of the world’s richest men has been quietly advancing a technology (not AI) that could change society forever and make early investors rich… It’s being called the “holy grail of power” and could help unlock a $40 trillion industry. See how you can get in before we cross the tipping point.

Donald Trump Declares Harsh Media Coverage of Him ‘No Longer Free Speech’ But ‘Illegal’

President Donald Trump has labeled negative media coverage of him as “illegal.” Continue Reading ➔

Charlie Kirk’s Company Takes On Comcast, NFL With Its Own Super Bowl Halftime Show

Super Bowl LX could be turning political with conservative organization Turning Point USA planning its own halftime show broadcast. Continue Reading ➔

Bitcoin Plummets To $118,000 As ETH, XRP, DOGE Take Heavy Losses On Trump Tariff Threat

Cryptocurrency markets are falling as president Trump signals a possible hike in U.S. tariffs on Chinese imports. Continue Reading ➔

$1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth This Much Today

Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 5 years by 10.45% on an annualized basis producing an average annual return of 25.22%. Currently, Alnylam Pharmaceuticals has a market capitalization of $57.78 billion. Continue Reading ➔

Tylenol Turmoil: Partisan Politics Fuel Confusion Over Pregnancy Risks, Poll Shows

KFF poll shows falling trust in the CDC and HHS chief RFK Jr. as misinformation and partisan divides shape public views on vaccines. Continue Reading ➔

FDA Clears Merck’s One-Minute Cancer Shot

FDA approves Merck’s Keytruda Qlex injection for adults with solid tumors. Merck expects it to be available in the U.S. in September. Continue Reading ➔

Information, charts, or examples contained in this email are for illustration and educational purposes only and not for individualized investment management. This message contains commercial elements, such as advertising and partner offers for which we may receive affiliate compensation. We only send these offers to those who have opted into our newsletter.

If you wish to no longer receive these offers, click on the unsubscribe link at the bottom of this email. Past performance is not indicative of future results. For these reasons, we strongly suggest trading in a DEMO/Simulated account.

The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices, or procedures of any company or entity mentioned or recommended in this email and have not determined if the statements and opinions of the advertiser are accurate, correct, or truthful.

If you use, act upon, or make decisions in reliance on information contained in this email or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates, and agents without fault.

2967 Dundas St. W. #990, Toronto, ON M6P 1Z2 | Phone Number: 917.672.7040

Prime Deals on NOW 🔥

Trump’s Favorite Crypto?? (And It’s Not His Own!)

RJ Hamster

Texas Royalty Plan: 28 Straight Years of Payment Increases

Texas Royalty Plan: 28 Straight Years of Payment Increases

Share this:

Like this:

Related articles